P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience

Abstract:

Background Vedolizumab (VDZ) has shown efficacy in the treatment of inflammatory bowel disease (IBD). Available data show better outcomes in naïve patients than in AntiTNFa experienced patients, and current ECCO guidelines support first-line use of VDZ since 2017. Nevertheless, reimbursement of VDZ was initially approved in Spain only in patients failing to at least one AntiTNFa agent (except contraindication) until January 2018 when, following a significative decrease in costs of VDZ, reimbursement was approved also in naïve patients. Our aim was to elucidate if our clinical use of vedolizumab have evolved after costs decrease, and if was associated with better clinical outcomes. Methods Retrospective review of all VDZ treated patients with at least 6 months of follow-up in a referral IBD Unit of a tertiary centre in Madrid (Spain) since December 2014. Demographics …

Año de publicación:

2020

Keywords:

Fuente:

google